Weekly Report: what happened at INCR last week (0715-0719)?

European Cannabis Companies Race To The Nasdaq: $1B In Tax Break On The Horizon

European cannabis companies are already planning initial public offerings on the Nasdaq. The potential rescheduling of cannabis to Schedule III in the U.S. And Germany's decriminalization have ignited optimism. Listing on Nasdaq offers European cannabis companies significant advantages. The DEA's proposed rule change to reclassify cannabis promises significant tax benefits.

Cannabis Investing In The Age Of Legalization With Julian Lin, Tim Seymour And Pablo Zuanic

Weekly Report: what happened at INCR last week (0708-0712)?

Weekly Report: what happened at INCR last week (0701-0705)?

Weekly Report: what happened at INCR last week (0624-0628)?

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

InterCure is a leading pharmaceutical/medical cannabis company based in Israel. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken. Pharmaceutical Cannabis industry is poised for significant growth in the coming years. InterCure stock should be considered poorly valued.

Weekly Report: what happened at INCR last week (0617-0621)?

Weekly Report: what happened at INCR last week (0610-0614)?

Weekly Report: what happened at INCR last week (0603-0607)?

Weekly Report: what happened at INCR last week (0527-0531)?

Weekly Report: what happened at INCR last week (0520-0524)?

Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ

InterCure is the leading seller of pharmaceutical cannabis outside North America. The company has a significant presence in Israel and is preparing to enter the German market by mid-2024. The potential rescheduling of cannabis in Germany and growing demand in Germany positions InterCure as a strategic player in the global market.

Intercure Ltd. Files SEC Report, Ensures Transparency

InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference

InterCure Ltd. Will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is scheduled for tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New York City. InterCure is the leading medical cannabis company outside of North America.

Weekly Report: what happened at INCR last week (0513-0517)?

Weekly Report: what happened at INCR last week (0506-0510)?

Weekly Report: what happened at INCR last week (0429-0503)?

CRVS, CTMX and NRXP are among premarket gainers

On the Move CRVS, CTMX and NRXP are among premarket gainers. XBP Europe Holdings (XBP) and Perficient (PRFT) are among the biggest premarket losers. Bitcoin reclaims the $65K level.

InterCure Reports Strong FY2023: Performance Paves the Way for Global Expansion

InterCure Ltd. Reported a total revenue of approximately USD 95.2 million in FY2023. The company reported an adjusted EBITDA of around USD 16.3 million, representing 17% of its total revenues. InterCure managed crisis impacts related to the Gaza conflict in the third quarter of 2023.